Cargando…

A new recombinant factor VIII: from genetics to clinical use

Advances in recombinant technology and knowledge about coagulation factor VIII (FVIII) are building a platform for new therapeutic options in patients with hemophilia A. The development of turoctocog alfa, a novel, high-purity, third-generation, B-domain truncated recombinant FVIII, has been produce...

Descripción completa

Detalles Bibliográficos
Autor principal:	Santagostino, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271724/ https://www.ncbi.nlm.nih.gov/pubmed/25548513 http://dx.doi.org/10.2147/DDDT.S73241

Ejemplares similares

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

A new recombinant factor VIII: from genetics to clinical use
por: Kannicht, Christoph, et al.
Publicado: (2015)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Recombinant factor VIII Fc for the treatment of haemophilia A
por: Hermans, Cedric, et al.
Publicado: (2021)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study
por: Nolan, Beatrice, et al.
Publicado: (2020)

PROTECT VIII Kids: BAY 94‐9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A
por: Santagostino, Elena, et al.
Publicado: (2020)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

Bacterial Production of Recombinant Coagulation Factor VIII Domains
por: Bashar, Saima, et al.
Publicado: (2023)

Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII
por: Grushin, K, et al.
Publicado: (2014)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII
por: Demers, Melanie, et al.
Publicado: (2022)

Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy
por: Meeks, Shannon L., et al.
Publicado: (2020)

Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
por: Curry, Nicola, et al.
Publicado: (2019)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
por: Schiavoni, Mario, et al.
Publicado: (2019)

Human coagulation factor VIII domain-specific recombinant polypeptide expression
por: Choi, Su Jin, et al.
Publicado: (2015)

Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII
por: Qu, Jingyao, et al.
Publicado: (2020)

Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision
por: Koç, Başak, et al.
Publicado: (2020)

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
por: Mancuso, Maria Elisa, et al.
Publicado: (2017)

Recombinant factor VIIa and factor VIII treatment for acquired factor VIII deficiency: a case of repeated thrombotic endotracheal occlusion in a mechanically ventilated patient
por: Lauer, Stefan, et al.
Publicado: (2011)

Stable Expression of Recombinant Factor VIII in CHO Cells Using Methotrexate-Driven Transgene Amplification
por: Orlova, N. A., et al.
Publicado: (2012)

Sedimentation Velocity Analytical Ultracentrifugation of Oxidized Recombinant Full-Length Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2020)

Blood Clotting Factor VIII: From Evolution to Therapy
por: Orlova, N. A., et al.
Publicado: (2013)

Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein
por: PETERS, R T, et al.
Publicado: (2013)

Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review
por: Hayden, Alexander, et al.
Publicado: (2022)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
por: Takeyama, Masahiro, et al.
Publicado: (2020)

Different impact of factor VIII products on inhibitor development?
por: van den Berg, H. Marijke
Publicado: (2016)

Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Real Life: One-Year Clinical and Economic Outcomes
por: Giraud, Romain, et al.
Publicado: (2021)

FACTOR VIII COAGULANT ACTIVITY AND FACTOR VIII-LIKE ANTIGEN: INDEPENDENT MOLECULAR ENTITIES
por: Zimmerman, Theodore S., et al.
Publicado: (1973)

Sucrose-Formulated Recombinant Factor VIII Dosing Flexibility in Prophylaxis Regimens: Experience from Postmarketing Surveillance Studies
por: Humphries, Thomas J., et al.
Publicado: (2015)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence
por: Dargaud, Yesim, et al.
Publicado: (2021)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

Repression of Factor VIII Inhibitor Development with Apoptotic Factor VIII-expressing Embryonic Stem Cells
por: Sakurai, Yoshihiko, et al.
Publicado: (2013)

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories
por: Sommer, J M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6tdfk7isputmk615qfhjoftjf7